collaborative-pharmacist-prescribing-doubles-heart-failure-medication-optimization-in-australian-clinics
Collaborative Pharmacist Prescribing Doubles Heart Failure Medication Optimization in Australian Clinics

Collaborative Pharmacist Prescribing Doubles Heart Failure Medication Optimization in Australian Clinics

Integrating collaborative pharmacist prescribing into community heart failure outpatient services substantially increases patient attainment of guideline-directed medical therapy while nearly doubling service capacity, according to a pre-post implementation study conducted within Queensland, Australia. The quasi-experimental evaluation, published in the International Journal of Clinical Pharmacy, assessed care delivered across two community health facilities within the Gold Coast Hospital and Health Service before and after establishing an integrated pharmacist prescribing clinic. Researchers discovered that the proportion of heart failure patients achieving optimal medication regimens by 90 days rose from 19.3 percent under physician-only care to 40.2 percent following the introduction of the collaborative model, representing an adjusted odds ratio of 2.6. By the time patients were discharged from the titration service, overall optimization rates reached 88.2 percent in the post-implementation cohort compared with 43.9 percent in the historical baseline group, corresponding to an adjusted odds ratio of 13.2.

Heart failure remains a severe clinical syndrome characterized by debilitating symptoms and high mortality, with published estimates indicating a 12 percent 30-day post-admission mortality rate and a 31 percent mortality rate at one year, generating an annual economic burden of nearly 2.7 billion Australian dollars. Evidence-based clinical guidelines establish four foundational pharmacological pillars for heart failure with reduced ejection fraction: renin-angiotensin system inhibitors or angiotensin receptor-neprilysin inhibitors, evidence-based beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter 2 inhibitors. When prescribed and titrated to guideline-recommended target doses or maximally tolerated doses, these quadruple therapies significantly lower hospital readmissions and decrease cardiovascular mortality. Despite these established benefits, real-world observational data and global registries show that fewer than 30 percent of heart failure patients achieve target doses at 12 months, largely due to clinical inertia, complex titration schedules, monitoring requirements, and severe outpatient staffing shortages.

To overcome these capacity bottlenecks, the Gold Coast Hospital and Health Service developed and incorporated a collaborative pharmacist prescribing clinic into its ambulatory care infrastructure. The public health service delivers acute, sub-acute, and community medical care across more than twenty healthcare facilities, catering to a regional population exceeding 711,000 residents across Southeast Queensland and northern New South Wales. Within this network, community heart failure titration services operating at the Helensvale Community Health Centre and the Robina Health Precinct had previously relied entirely on cardiology advanced trainees—specialist medical registrars delivering clinical care under the overarching governance of supervising consultant cardiologists. Because these advanced trainees could accommodate no more than twelve patient appointments per week despite the service receiving up to 500 regional patient referrals each year, patient appointment intervals were prolonged and medication titration was frequently delayed.

The formal investigation examined clinical and operational metrics across 302 consecutive adult outpatients presenting with heart failure and a left ventricular ejection fraction below 50 percent who required active medication titration. The study population encompassed both heart failure with reduced ejection fraction, defined as an ejection fraction of 40 percent or lower, and heart failure with mildly reduced ejection fraction, defined as an ejection fraction between 41 and 49 percent. The retrospective pre-implementation cohort comprised 98 patients managed between December 2021 and December 2022, while the prospective post-implementation cohort followed 204 patients between March 2023 and March 2024. The two evaluation phases were divided by a deliberate two-month clinical washout interval during January and February 2023 to avoid patient crossover. Across the entire study cohort, 285 individuals, or 94.4 percent, presented with a left ventricular ejection fraction of 40 percent or less, with equal distribution across both observation periods.

Under the collaborative prescribing framework enabled by Australian state healthcare legislation, care delivery was redesigned around a structured clinical division of responsibility between medical registrars and an advanced practice cardiology pharmacist. Cardiology advanced trainees conducted the initial comprehensive diagnostic and clinical assessment, retaining direct oversight of clinically unstable or decompensated patients displaying New York Heart Association Class IV symptoms or overt fluid overload. Conversely, patients who were euvolemic and clinically stable were triaged directly to the collaborative pharmacist titration clinic. The pharmacist, who held consultant-level cardiology credentialing from the Australian New Zealand College of Advanced Pharmacy and seventeen years of heart failure management experience, conducted 30-minute joint intake consultations alongside a dedicated clinical nurse consultant. Titration pathways adhered to standardized clinical thresholds endorsed by the local health service medicines advisory committee, with the medical registrar retaining prescription authorization.

Statistical evaluation using segmented Poisson interrupted time-series regression revealed that the introduction of collaborative pharmacist prescribing served as the principal driver of medication improvement, yielding an incidence rate ratio of 1.99 at 90 days and 2.07 at service discharge. The time-series modeling established that underlying temporal trends, time-by-intervention interactions, and cyclical seasonality had no statistically significant effect on optimization trajectories. Because monthly titration rates converged into distinct pre- and post-intervention step changes, multivariable logistic regression models were constructed to adjust for baseline imbalances, including resting heart rate, atrial fibrillation, and initial usage rates of mineralocorticoid receptor antagonists and SGLT2 inhibitors. Even after adjusting for these clinical covariates, the collaborative care intervention remained strongly associated with higher odds of medication optimization, while the median duration to service discharge remained identical across both cohorts at 98 days.

Detailed class-by-class medication analysis demonstrated that the post-implementation collaborative pathway achieved superior dose titration across all four guideline-directed drug classes at the 90-day milestone. The most pronounced therapeutic gain occurred in the prescribing and titration of mineralocorticoid receptor antagonists, where the proportion of patients attaining full target doses climbed from 10.5 percent during the baseline period to 39.0 percent following implementation of the collaborative clinic. Patients who did not achieve guideline target dosages were classified as medically optimized if they reached predefined maximally tolerated doses restricted by documented contraindications, symptomatic hypotension with systolic blood pressure of 95 mmHg or lower, bradycardia below 65 beats per minute, impaired renal function, or hyperkalemia. This objective framework ensured that optimization reflected genuine physiological tolerance rather than therapeutic inertia or premature discontinuation.

In addition to pharmacological gains, the restructured model generated substantial improvements in outpatient clinic throughput and service responsiveness. Following the implementation of the collaborative pharmacist clinic, the mean number of new heart failure patients enrolled each month increased from 9 to 16, representing a statistically significant gain in clinic capacity. Concurrently, the operational interval between patient review visits shortened dramatically: while pre-implementation follow-up intervals exhibited a median delay of 49 days between early visits and 63 days between later appointments, post-implementation visit intervals dropped to a median of 28 days. By transferring ongoing routine medication titration to the pharmacist-led clinic, the service accelerated dose escalation schedules while simultaneously liberating medical registrars to evaluate new outpatient referrals and manage unstable cases.

Analysis of secondary safety endpoints showed no statistically significant differences between the cohorts regarding unscheduled all-cause or heart failure-specific hospital readmissions or patient mortality at 30 days and six months. No patient deaths were recorded in the baseline cohort, whereas six deaths occurred in the post-implementation group, a difference that remained statistically non-significant given the low overall event rate. Detailed clinical auditing revealed that four of the six post-implementation deaths stemmed from documented non-cardiovascular terminal conditions, including pancreatic carcinoma, glioblastoma multiforme, metastatic colorectal cancer, and septic shock secondary to an infected diabetic foot ulcer. The remaining two deaths occurred outside the regional health facility network, preventing verification of the underlying cause of death, but no fatal events were attributed to medication titration adverse effects.

Patient-reported outcome measures evaluated among post-implementation participants demonstrated meaningful gains in health-related quality of life and treatment perception. Disease-specific quality of life, quantified using the 12-item Kansas City Cardiomyopathy Questionnaire, improved significantly from a baseline mean score of 74.0 to 84.8 at clinic discharge. General health status assessed through the EuroQol five-dimension five-level visual analogue scale similarly advanced from 73.0 to 79.5. Evaluation of the Beliefs about Medicines Questionnaire documented an increase in patients’ perceived necessity of their cardiovascular medications, rising from 19.5 to 20.6, while self-reported adherence scores captured via the Medication Adherence Report Scale remained consistently elevated across the care pathway, moving from 24.3 to 24.4.

The study authors identified several methodological boundaries, emphasizing that the single-center observational design utilized a single highly experienced consultant pharmacist, which may influence direct generalizability to health systems lacking equivalent clinical training or governance pathways. Furthermore, because patient management involved dynamic movement between registrars and the prescribing pharmacist depending on clinical complexity, the outcomes reflect the combined efficacy of a multidisciplinary team rather than isolated pharmacist autonomy. The authors noted that future multicenter trials must evaluate longitudinal safety, hard clinical outcomes, and health economic sustainability across diverse geographic settings. Nevertheless, these real-world findings demonstrate that structured collaborative pharmacist prescribing models offer a viable, scalable strategy to overcome therapeutic inertia and achieve rapid medication titration in community heart failure care.

Subject of Research: Collaborative pharmacist medication prescribing in community heart failure clinics

Article Title: Collaborative pharmacist prescribing in community heart failure clinics: a pre-post intervention comparison

Article References: Percival, M., Hattingh, L., Jayasinghe, R., Millhouse, J., Crook, J., De Wet, C., Hughes, I., & Freeman, C. (2026). Collaborative pharmacist prescribing in community heart failure clinics: a pre-post intervention comparison. International Journal of Clinical Pharmacy, 48(5), 2050-2063. https://doi.org/10.1007/s11096-026-02186-0

Image Credits: AI Generated

DOI: 10.1007/s11096-026-02186-0

Keywords: heart failure, collaborative prescribing, pharmacist-led care, guideline-directed medical therapy, reduced ejection fraction, interrupted time series, titration clinics, community health services, clinical pharmacy, cardiology advanced trainees, service efficiency, mineralocorticoid receptor antagonists, health-related quality of life, medication optimization, Gold Coast Health, outpatient cardiology, prescribing models